Multiple Sclerosis Clinical Trial

Photobiomodulation Therapy in Persons With Multiple Sclerosis

Summary

This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.

View Full Description

Full Description

Persons with multiple sclerosis (MS) MS commonly experience muscle weakness and fatigue which may contribute to the commonly reported symptomatic fatigue. Photobiomodulation therapy (PBMT) induced with light in the visible red to near infrared (VIS/NIR) region of the spectrum (600-1000 nm) can stimulate cytochrome c oxidase and improve mitochondrial function. PBMT is an emerging therapeutic modality for soft tissue injury, chronic inflammation, neurodegeneration , and retinal diseases. PBMT has also been used to enhance muscle endurance, strength and recovery in healthy adults. We propose that in persons with MS, PBMT will 1) enhance regional muscle endurance after acute treatment and 2) enhance functional endurance after extended treatment. We will also test to determine if improvements are due to central or peripheral neuromuscular or cardiovascular mechanisms. Final, we will explore if regional PBMT can result in systemic anti-inflammatory effects.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsing remitting MS,
Independent or ambulatory with minimal aid.
Must be able to move foot (ankle dorsiflexion) at least moderately forcibly against gravity (manual muscle test score 3-5)
Subjects must be able to walk for 6 minutes independently with no or minimal use of an assistive device.

Exclusion Criteria:

No noticeable left right ankle strength asymmetry
No exacerbations (MS attacks) or immunosuppressive therapy use within the previous 6 months
No concurrent infection or known cardiovascular disease including having a pacemaker; or other serious medical co-morbidity including metabolic, mitochondrial, autoimmune, diseases or other co-existing neurologic conditions.
Not involved in any clinical trial or other research that could confound results.
Must not be pregnant
Must not have an active diagnosis of cancer

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

21

Study ID:

NCT03691766

Recruitment Status:

Completed

Sponsor:

Marquette University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Marquette University
Milwaukee Wisconsin, 53201, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

21

Study ID:

NCT03691766

Recruitment Status:

Completed

Sponsor:


Marquette University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider